Clinical Trial Update: A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 results for Tarceva (erlotinib) in untreated, good-prognosis patients with advanced non-small cell lung cancer have been posted. The trial status is com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: University of Utah | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-11-21